Accelerated Discovery of Safer, More Efficient Fully Human Antibodies in 3 Months
Fully human antibodies, entirely encoded by human genes, offer a significant advantage in antibody drug development. They trigger minimal immune response (immunogenicity) in patients, leading to improved safety and tolerance compared to traditional antibody therapies. This approach also focuses on identifying high-affinity and highly specific antibodies, ensuring they effectively target the desired molecules. Previously, researchers relied on humanized mice, genetically modified to produce human antibodies, for this purpose.
Built for speed and safety, our fully human antibody discovery platform combines AbDrop™ microdroplet single-B-cell screening with Cyagen’s HUGO-Ab™ fully human antibody mice to deliver developable, fully human leads without a humanization step. We can screen millions of plasma B cells within a week, preserve natural VH/VL pairing through single-cell barcoding and NGS, and advance confirmed binders into high-throughput expression and multi-assay validation (ELISA, SPR, FACS; functional readouts as required). The platform supports proteins, complex membrane proteins, peptides, and small molecules, and you can provide your own antigen or have Biointron produce it.
Our antibody discovery services also include:
